ストックスクリーナーアプリを入手
12.85
16.82%
1.85
前日終値:
$11.00
開ける：
$10.83
24時間の取引高:
44,494
Relative Volume:
0.74
時価総額：
$152.82M
収益：
$6.67M
当期純損益:
$-47.55M
株価収益率:
-8.5667
EPS:
-1.5
ネットキャッシュフロー:
$-17.44M
1週間 パフォーマンス:
+7.08%
1か月 パフォーマンス:
-14.84%
6か月 パフォーマンス:
+2,413%
1年 パフォーマンス:
+2,413%
1日の値動き範囲:
$10.83
$12.92
1週間の範囲:
$10.83
$12.92
52週間の値動き範囲:
$10.83
$21.40
Crescent Biopharma Inc Stock (CBIO) Company Profile
CBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
12.85 | 152.82M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-14 | 開始されました | Wedbush | Outperform |
| 2025-06-25 | 開始されました | Stifel | Buy |
| 2025-03-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-11 | 開始されました | Noble Capital Markets | Outperform |
| 2024-07-26 | ダウングレード | TD Cowen | Buy → Hold |
| 2023-12-22 | 開始されました | CapitalOne | Overweight |
| 2021-11-12 | アップグレード | Jefferies | Hold → Buy |
| 2021-04-29 | 再開されました | Stephens | Overweight |
| 2021-02-10 | 開始されました | Piper Sandler | Overweight |
| 2020-05-21 | 開始されました | Raymond James | Outperform |
| 2019-11-14 | 開始されました | ROTH Capital | Buy |
| 2019-08-05 | ダウングレード | Jefferies | Buy → Hold |
| 2019-08-05 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | ダウングレード | SunTrust | Buy → Hold |
| 2019-04-12 | 開始されました | Piper Jaffray | Overweight |
| 2019-01-04 | 開始されました | Oppenheimer | Outperform |
| 2018-12-18 | 開始されました | H.C. Wainwright | Buy |
| 2018-02-12 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-12-08 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 開始されました | Chardan Capital Markets | Buy |
| 2017-06-06 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-07-26 | 開始されました | SunTrust | Buy |
| 2016-06-30 | 開始されました | Rodman & Renshaw | Buy |
| 2015-03-17 | 繰り返されました | Stifel | Buy |
すべてを表示
Crescent Biopharma Inc (CBIO) 最新ニュース
Wedbush Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $27 - 富途牛牛
Crescent Biopharma (NASDAQ:CBIO) Cut to “Sell” at Wall Street Zen - Defense World
Crescent Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Crescent Biopharma: Q2 Earnings Snapshot - Greenwich Time
Crescent Biopharma Advances Cancer Therapeutics with CR-001 and ADCs, Completes Merger and Nasdaq Listing - AInvest
Crescent Biopharma's Promising Pipeline and Strategic Positioning Support Buy Rating - AInvest
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
CRESCENT BIOPHARMA, INC. SEC 10-Q Report - TradingView
Crescent Biopharma Raises $200M to Accelerate Next-Gen Cancer Therapies Development Following Strategic Merger - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Stock Rating Upgraded by Wall Street Zen - Defense World
What is Wedbush’s Estimate for CBIO Q2 Earnings? - Defense World
Wedbush Begins Coverage on Crescent Biopharma (NASDAQ:CBIO) - Defense World
Wedbush Initiates Crescent Biopharma at Outperform With $27 Price Target - MarketScreener
Wedbush Initiates Coverage of Crescent Biopharma (CBIO) with Outperform Recommendation - MSN
Crescent Biopharma (NASDAQ:CBIO) Upgraded by Wall Street Zen to Sell Rating - Defense World
Crescent Biopharma (NASDAQ:CBIO) Stock Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World
Crescent Biopharma Snatches Oncology Star Jan Pinkas—Here's Why This Could Be a Game-Changer - AInvest
Crescent Biopharma appoints Jan Pinkas as chief scientific officer - Investing.com
Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer - GlobeNewswire
ADC Pioneer with ELAHERE Success Record Joins Crescent Biopharma as Chief Scientific Officer - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200 Day Moving Average – Should You Sell? - Defense World
Why Did Crescent Biopharma Drop 10.72%? - AInvest
Stifel Initiates Coverage of Crescent Biopharma (CBIO) with Buy Recommendation - MSN
Crescent Biopharma: A Promising Investment in the Growing PD-(L)1-Targeting Market - TipRanks
Petri Dish: Turkish firm backs Harvard lab, Isomorphic opens in Cambridge - The Business Journals
Crescent Biopharma Completes Merger with GlycoMimetics - TipRanks
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks
Massive $200M Biotech Deal: Crescent Biopharma Secures Funding for Cancer Breakthrough Pipeline - Stock Titan
Crisis as catalyst: From Chernobyl evacuation to biotech innovation - BioXconomy
Gyre Therapeutics announces first doing in Phase 1 trial of F230 - TipRanks
How To Trade (GYRE) - news.stocktradersdaily.com
GlycoMimetics Stockholders Approve Crescent Biopharma Merger - AInvest
GlycoMimetics Stockholders Approve Merger with Crescent Biopharma - TipRanks
Is Costco's BNPL Push a Catalyst for Big-Ticket E-Commerce? - The Globe and Mail
GlycoMimetics Stockholders Approve Crescent Biopharma Merger and Reverse Stock Split - AInvest
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Hemophilia with Inhibitor Market Statistics Expected - openPR.com
A.I. Drone Operations Flourishing as Global Quantum Computing Market Expected to Reach $5.3 Billion By 2029 - The Globe and Mail
Forge Resources Announces Closing of Further Interest to 80% in Fully Permitted Coal Project, Colombia - The Globe and Mail
Quantum Computing Technology Evolving as Larger Scale of Applications & Uses Skyrockets - The Globe and Mail
AI Analyst Flags Key Risks and Upside for Nvidia Ahead of Earnings - The Globe and Mail
Prediction: SoundHound AI Stock Will Beat the Market. Here's Why. - The Globe and Mail
Zacks Investment Ideas feature highlights: CyberArk, Lam Research and monday.com - The Globe and Mail
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
(GYRE) Long Term Investment Analysis - news.stocktradersdaily.com
SBAC Stock Rises 12% Year to Date: Will the Trend Continue? - The Globe and Mail
GYRE Trading Resumes After Temporary Halt | GYRE Stock News - GuruFocus
Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility - GuruFocus
Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility | GYRE Stock News - GuruFocus
Factor Investing in Focus: What ETFs Say About Market Direction - The Globe and Mail
Crescent Biopharma Inc (CBIO) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
3.39%
大文字化:
|
ボリューム (24 時間):